Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

It's hard to believe how large Biogen's market opportunity is, now that the FDA has approved its Alzheimer's drug.

The Upside for Biogen Is Absolutely Wild

Many doctors don't like the drug, and the trial data was underwhelming. Nonetheless, Biogen's Alzheimer's drug was approved-- and the market opportunity is huge.

Why Biogen's FDA Approval Is Shocking

Among the stocks in Warren Buffet's Berkshire Hathaway Inc. (NYSE: BRK-B) portfolio, Thursday's biggest loser was Biogen.

How Will the Drop in Biogen's Share Price Hit Buffett's Portfolio?

INCHEON, Korea and CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for BYOOVIZ™, a biosimilar candidate referencing Lucentis®1 (ranibizumab), also known as SB11. Ranibizumab is an anti-VEGF (vascular endothelial growth factor) for retinal vascular disorders, which are a leading cause of blindness. BYOOVIZ has been recommended for approval for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to diabetic macular oedema (DME), proliferative diabetic retinopathy (PDR), visual impairment due to macular odemea secondary to retinal vein occlusion (branch RVO or central RVO) and visual impairment due to choroidal neovascularization (CNV) in the European Union (EU).

Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Ranibizumab Biosimilar, BYOOVIZ™

The surprise approval of Aduhelm provided a big financial boost to Biogen. The biopharma spent the last few years repurchasing billions worth of stock on the dips and has a $4 billion authorization remaining.

Biogen: Score A Big Win For Buybacks

AvalonBay Communities

Blackbaud

Federal Realty Investment Trust

As of Wednesday, the Historical Low Price-Sales model portfolio has returned approximately 16.13% since the Jan. 1 rebalance date and over 244% since the model portfolio's inception in 2010 according to the GuruFocus Model Portfolios page. The top-performing stocks are Biogen Inc. ( BIIB , Financial), CI Financial Group ( CIXX , Financial), Federal Realty Investment Trust ( FRT , Financial), Blackbaud Inc. ( BLKB , Financial) and AvalonBay Communities Inc. ( AVB , Financial).

Top-Performing Stocks in Historical Low Price-Sales Portfolio as of June

Shares of Biogen Inc. were up 0.8% in premarket trading on Wednesday after the company and Eisai Inc. said they plan to speed up the completion of what is called a "confirmatory" clinical trial for its recently approved Alzheimer's disease treatment. In the weeks since the drug's approval in the U.S., Aduhelm has faced criticism over how it was priced and whether or not the clinical data were strong enough to support the approval.

Biogen now says it plans to complete 'confirmatory' study for Alzheimer's drug earlier than required

The U.S. Food and Drug Administration approved the first new Alzheimer's drug in decades over the objection of agency statisticians who said there was insufficient evidence to support approval, according to newly released internal memos.

The Wall Street Journal: FDA approved Biogen Alzheimer's drug despite some objections by staff

Here's one longtime healthcare expert's perspective.

Why Biogen Isn't a Buy After Its Alzheimer's Drug Approval

BioMarin Pharmaceutical

Eli Lilly

Ultragenyx Pharmaceutical

Roche Holding AG

FDA approval of Biogen's Aduhelm for Alzheimer's should be broadly supportive of biotechnology and pharmaceutical stocks as it signals the agency is willing to be flexible to make important drugs. The rerating of Biogen shares following the FDA decision demonstrates the potential of innovation in the biopharmaceutical industry to generate significant alpha for investors.

Alzheimer's Approval Validates Biopharmaceutical Innovation

Beyond its lofty price tag, there are other impediments to big sales of aducanamab that the market largely ignored this week.

3 More Reasons Biogen's Alzheimer's Drug Will Underperform Wall Street Expectations

One of these agreements could be more important than the other.

Biogen's Alzheimer's Drug Deals With CVS and Cigna: What Investors Should Know

Biogen (BIIB) is developing its monoclonal antibody candidate, BIIB059, as a potential treatment for active systemic lupus erythematosus.

Biogen (BIIB) Initiates Late-Stage Study on Lupus Candidate

The bottom line: The FDA can do what it wants to do.

Why Did the FDA Approve Biogen's Alzheimer's Disease Drug After an Advisory Panel Recommended Against It?

The FDA's approval of the first new drug to treat Alzheimer's disease in about 20 years has attracted investors' attention toward the biotech sector while sparking new controversies.

Biogen's Alzheimer's Drug Approval Puts Biotech ETFs in Spotlight

Innoviva

SAGE Therapeutics

SIGA Technologies

Searching for undervalued biotech stocks? Here are 4 biotech stocks to buy for a mix of value and growth in any portfolio.

4 Undervalued Biotech Stocks That Belong On Every Investor's Buy List

Biogen (BIIB) ends development of investigational anti-tau antibody, gosuranemab for treating Alzheimer's disease after the phase II TANGO study showed no benefit to patients.

Biogen (BIIB) Ends Development of Anti-Tau Alzheimer's Drug

Biogen Inc (NASDAQ: BIIB) has dosed the first patient in the TOPAZ-1 Phase 3 study evaluating BIIB059 in participants with active systemic lupus erythematosus (SLE). The 540-subject trial will assess the efficacy and safety of BIIB059 compared with placebo.

Biogen Commences Dosing In Late-Stage Systemic Lupus Erythematosus Study With BIIB059

CAMBRIDGE, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the first patient has been dosed in the global clinical study, TOPAZ-1. The Phase 3 study will evaluate the clinical efficacy and assess the safety of BIIB059, a first in-class, humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2), as compared to placebo, in participants with active systemic lupus erythematosus (SLE). TOPAZ-1 is expected to be conducted at approximately 135 sites worldwide and aims to enroll 540 adults with active SLE.

Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study

Biogen Inc (NASDAQ: BIIB) has four other Alzheimer's candidates in its clinical pipeline behind recently-approved Aduhelm, of which one has just been canned. The biotech says that gosuranemab, the second leading drug target in Alzheimer's, flat failed its Phase 2 and will now be taken out and dumped.

Biogen Discontinues Tau Antibody Program For Alzheimer's After Mid-Stage Study Flops

Shares of Biogen Inc. fell nearly 1% in the extended session after the pharma company said it will halt the development of an antibody drug aimed at treating Alzheimer's disease after a study showed no benefit to patients. Another of the company's drugs aimed at the disease won approval earlier this month.

Biogen halts development of antibody drug aimed at Alzheimer's

CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced topline results from its Phase 2 TANGO study of gosuranemab (BIIB092), an investigational anti-tau antibody that was being evaluated as a potential treatment for Alzheimer's disease.

Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer's Disease

A 70-year-old man from Rhode Island on Wednesday was the first to receive an infusion outside of a clinical trial of Biogen's Alzheimer's drug, Aduhelm.

Patient receives first infusion of Biogen's controversial Alzheimer's drug

A U.S. hospital on Wednesday will give the first infusion of Biogen Inc's (NASDAQ: BIIB) expensive, controversial Alzheimer's drug approved a week ago. Medicare had even said what it would pay for the treatment, but some doctors were upset by its approval last week.

First Patient Set To Receive Biogen's Alzheimer's Drug: Reuters

A US consumer rights group has said the acting commissioner of the Food and Drug Administration (FDA) Janet Woodcock and other officials should “immediately resign” over the regulator's approval of Biogen Inc's (NASDAQ:BIIB) controversial Alzheimer's drug, aducanumab. In an open letter on Wednesday, Public Citizen, a Washington DC-based special interest group and think tank founded by former presidential candidate Ralph Nader, described the FDA's approval of aducanumab last week as “reckless”, highlighting the “nearly unanimous conclusion of an independent advisory panel of experts that there was insufficient evidence that the drug was effective”.

News for Biogen Stock (BIIB)